Lecanemab and Vascular-Amyloid Deposition in Brains of People With Down Syndrome.
Sign Up to like & getrecommendations! Published in 2024 at "JAMA neurology"
DOI: 10.1001/jamaneurol.2024.2579
Abstract: Importance Anti-β-amyloid immunotherapy using lecanemab is becoming increasingly available to patients with Alzheimer disease (AD). Individuals with Down syndrome (DS) develop AD neuropathology by age 40 years, representing a significant cohort of genetically determined AD.… read more here.
Keywords: brain; lecanemab vascular; amyloid; brains people ... See more keywords